2022
Evidence of Racial Disparities in the Lung Cancer Screening Process: a Systematic Review and Meta-Analysis
Kunitomo Y, Bade B, Gunderson CG, Akgün KM, Brackett A, Tanoue L, Bastian LA. Evidence of Racial Disparities in the Lung Cancer Screening Process: a Systematic Review and Meta-Analysis. Journal Of General Internal Medicine 2022, 37: 3731-3738. PMID: 35838866, PMCID: PMC9585128, DOI: 10.1007/s11606-022-07613-2.Peer-Reviewed Original ResearchConceptsLung cancer screeningLCS participationLung cancer mortalityScreening ratesWhite patientsSystematic reviewCancer mortalityPatient populationRacial disparitiesPatient studiesLung cancer screening processAllied Health Literature databasesLow-dose chestHigh-risk individualsMethodsA systematic reviewCancer screening processFull-text reviewTitles/abstractsWeb of ScienceBlack patientsDatabase inceptionCancer screeningClinical trialsInclusion criteriaProvider awareness
2021
Racial Differences in Adherence to Lung Cancer Screening Follow-up A Systematic Review and Meta-analysis
Kunitomo Y, Bade B, Gunderson CG, Akgün KM, Brackett A, Cain H, Tanoue L, Bastian LA. Racial Differences in Adherence to Lung Cancer Screening Follow-up A Systematic Review and Meta-analysis. CHEST Journal 2021, 161: 266-275. PMID: 34390706, DOI: 10.1016/j.chest.2021.07.2172.Peer-Reviewed Original ResearchConceptsLung cancer screeningLung cancer mortalityCancer mortalityCancer screeningLow adherenceSystematic reviewAnnual lung cancer screeningLung cancer mortality benefitLow-dose chest CTEligible black patientsAllied Health Literature databasesA Systematic ReviewRate of adherenceHigh-risk individualsUnited States Preventive Services TaskforceFull-text reviewHealth Literature databasesWeb of ScienceLCS adherenceLCS participationBlack populationMortality benefitWhite patientsBlack patientsInitial screening results
2016
Lung cancer screening
Tanoue LT. Lung cancer screening. Current Opinion In Pulmonary Medicine 2016, 22: 327-335. PMID: 27159896, DOI: 10.1097/mcp.0000000000000287.Peer-Reviewed Original ResearchConceptsLung cancer screeningLow-dose chestCancer screeningUS Preventive Services Task ForceNational Lung Screening TrialFuture screening practicesLung cancer mortalityHigh-risk individualsIndividualized risk assessmentTobacco treatmentCancer mortalityFalse-positive resultsLung cancerPositive screenChest radiographyScreening practicesInvasive testingScreening TrialLung cancer biomarkersMultidisciplinary programHigh false positive ratePotential harmOngoing studiesChestRelative reduction
2006
Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities.
Decker RH, Tanoue LT, Colasanto JM, Detterbeck FC, Wilson LD. Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities. Oncology 2006, 20: 899-905; discussion 905-8, 913. PMID: 16922260.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerPoor baseline pulmonary functionCurative treatment alternativeInoperable early stageSingle-modality radiotherapyComorbid medical illnessesBaseline pulmonary functionBetter overall survivalMinority of patientsRadiotherapy dose escalationDefinitive treatment optionEarly-stage patientsOverall survival dataNew treatment modalitiesMediastinal nodalAdvanced diseaseCurative resectionDistant failureOverall survivalPulmonary functionDose escalationDefinitive managementMedical illnessCancer mortalityEvaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: Assessment and conventional radiotherapy.
Decker RH, Tanoue LT, Colasanto JM, Detterbeck FC, Wilson LD. Evaluation and definitive management of medically inoperable early-stage non-small-cell lung cancer. Part 1: Assessment and conventional radiotherapy. Oncology 2006, 20: 727-36. PMID: 16841796.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerPoor baseline pulmonary functionCurative treatment alternativeSingle-modality radiotherapyComorbid medical illnessesBaseline pulmonary functionBetter overall survivalEarly-stage patientsMinority of patientsRadiotherapy dose escalationDefinitive treatment optionOverall survival dataMediastinal nodalAdvanced diseaseCurative resectionDistant failureOverall survivalPulmonary functionDose escalationDefinitive managementMedical illnessCancer mortalityTreatment optionsRadiofrequency ablation